Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy.

[1]  N. Van Rooijen,et al.  Role of lung-marginated monocytes in an in vivo mouse model of ventilator-induced lung injury. , 2009, American journal of respiratory and critical care medicine.

[2]  S. Verbeek,et al.  Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between FcγRI and FcγRIV1 , 2008, The Journal of Immunology.

[3]  G. Meijer,et al.  Anti-β1 Integrin Antibody Reduces Surgery-Induced Adhesion of Colon Carcinoma Cells to Traumatized Peritoneal Surfaces , 2008, Annals of surgery.

[4]  S. Meijer,et al.  Blocking α2 integrins on rat CC531s colon carcinoma cells prevents operation‐induced augmentation of liver metastases outgrowth , 2007, Hepatology.

[5]  S. Ménard,et al.  Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. , 2007, Cancer research.

[6]  Jianming Xu,et al.  Preoperative Hepatic and Regional Arterial Chemotherapy in the Prevention of Liver Metastasis After Colorectal Cancer Surgery , 2007, Annals of surgery.

[7]  K. Sales,et al.  EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges , 2007, British Journal of Cancer.

[8]  C. Glover,et al.  Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma , 2007, The British journal of surgery.

[9]  N. Bird,et al.  Biology of colorectal liver metastases: A review , 2006, Journal of surgical oncology.

[10]  J. Leusen,et al.  The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. , 2006, Cancer research.

[11]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[12]  C. Landen,et al.  Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. , 2005, Cancer research.

[13]  P. Bruhns,et al.  FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .

[14]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[15]  F. Braet,et al.  Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis , 2004, International journal of cancer.

[16]  E. Van Cutsem,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[18]  S. Yasuda,et al.  Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma , 2004, Cancer.

[19]  T G Cotter,et al.  Excisional surgery for cancer cure: therapy at a cost. , 2003, The Lancet. Oncology.

[20]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Kuppen,et al.  Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model. , 2003, Molecular immunology.

[22]  H. Mellstedt,et al.  Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A , 2003, International journal of cancer.

[23]  M. Cuesta,et al.  Immune‐stimulating effects of low‐dose perioperative recombinant granulocyte–macrophage colony‐stimulating factor in patients operated on for primary colorectal carcinoma , 2001, The British journal of surgery.

[24]  Y. Takagi,et al.  Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. , 2000, Annals of surgery.

[25]  N. Cheung,et al.  Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors , 2000, Cancer Immunology, Immunotherapy.

[26]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[27]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[28]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[29]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[30]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Houghton,et al.  Fc receptors are required in passive and active immunity to melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Meijer,et al.  Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver , 1996, Hepatology.

[33]  R. Beelen,et al.  Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon γ , 1994, Cancer Immunology, Immunotherapy.

[34]  N. Rooijen,et al.  Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate , 1990, Cell and Tissue Research.

[35]  L. Aarden,et al.  Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining. , 1988, Journal of immunological methods.

[36]  P. Tynan,et al.  Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy , 1982, Cell.

[37]  S. Sternberg,et al.  A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. , 1974, Journal of the National Cancer Institute.

[38]  G. Fleuren,et al.  The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma , 2004, Clinical & Experimental Metastasis.